Nine Square Therapeutics
CompanyUnited States
Nine Square Therapeutics develops 2 assets, the furthest preclinical (Parkin (PD) in Parkinson's disease). Mostly small molecule; based in the United States.
- 2
- Assets
- Furthest stage
- Preclinical
- Raised
- US$54.2m
- 0
- Trials
- 0
- Signals
Pipeline
2Promotes Parkin activity to clear dysfunctional mitochondria and protect dopaminergic neurons.
Preclinical, Small molecule, Parkinson's disease
Activates TRPML1 to enhance autophagic removal of toxic aggregates and protect neuronal health.
Preclinical, Small molecule, Alzheimer's disease, amyotrophic lateral sclerosis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Funding rounds and grants2
- People14
- Similar companies6